Updated overall survival (OS) analysis from a phase III study of sunitinib vs placebo in patients (pts) with advanced, unresectable pancreatic neuroendocrine tumor (NET)
S. Faivre
Updated overall survival (OS) analysis from a phase III study of sunitinib vs placebo in patients (pts) with advanced, unresectable pancreatic neuroendocrine tumor (NET)
S. Faivre